MedTrace Logo

A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling

NCT05492734 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-09-02

No results posted yet for this study

Summary

This is a Phase I, open-label, single-dose, 1-period study to compare EDG-5506 concentrations measured from venous and capillary blood sampling in healthy adult subjects.

EDG-5506 is an investigational product designed to selectively modulate a fast skeletal muscle motor protein called myosin that is part of the contraction machinery of the damage-prone muscle fibers.

Conditions

  • Muscular Dystrophies

Interventions

DRUG

EDG-5506

single oral dose

Sponsors & Collaborators

  • Edgewise Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Sam Collins, MBBS, PhD · Edgewise Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-12
Primary Completion
2022-08-19
Completion
2022-08-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05492734 on ClinicalTrials.gov